AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
Log in

NASDAQ:ICCCImmuCell Stock Price, Forecast & News

$4.56
+0.10 (+2.24 %)
(As of 06/3/2020 03:20 PM ET)
Add
Compare
Today's Range
$4.56
Now: $4.56
$4.60
50-Day Range
$4.02
MA: $4.31
$4.68
52-Week Range
$3.70
Now: $4.56
$8.13
Volume688 shs
Average Volume47,039 shs
Market Capitalization$32.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.72 million
Cash Flow$0.14 per share
Book Value$4.02 per share

Profitability

Net Income$-1,300,000.00

Miscellaneous

Employees47
Market Cap$32.88 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

How has ImmuCell's stock been impacted by COVID-19 (Coronavirus)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICCC shares have increased by 6.0% and is now trading at $4.56. View which stocks have been most impacted by Coronavirus.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for ImmuCell.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) released its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. The biotechnology company had revenue of $4.91 million for the quarter. ImmuCell had a negative net margin of 10.98% and a negative return on equity of 5.35%. View ImmuCell's earnings history.

Has ImmuCell been receiving favorable news coverage?

News stories about ICCC stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ImmuCell earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutImmuCell.

Are investors shorting ImmuCell?

ImmuCell saw a drop in short interest in May. As of May 15th, there was short interest totaling 22,200 shares, a drop of 31.9% from the April 30th total of 32,600 shares. Based on an average daily trading volume, of 29,500 shares, the short-interest ratio is currently 0.8 days. Approximately 0.4% of the shares of the stock are sold short. View ImmuCell's Current Options Chain.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (5.36%) and BlackRock Inc. (0.18%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche. View institutional ownership trends for ImmuCell.

Which major investors are selling ImmuCell stock?

ICCC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP. View insider buying and selling activity for ImmuCell.

Which major investors are buying ImmuCell stock?

ICCC stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche. View insider buying and selling activity for ImmuCell.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $4.56.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $32.88 million and generates $13.72 million in revenue each year. ImmuCell employs 47 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.